Clinical trials: how technology is driving digitisation

November 06, 2018 – Breakthrough innovation specialist Cambridge Consultants has designed ‘Verum’, a digital health platform that will reshape the way healthcare is delivered. The platform remotely monitors patients and provides machine learning-driven predictions around conditions or disease states. Verum’s initial test application focuses on clinical trials, where huge efficiencies can be achieved by identifying and mitigating the effect of patient stress on trial outcomes.

Stress is an underlying cause of behavioural and disease states and yet it is poorly characterized, leading to badly controlled clinical trials with average drop-out rates at 30%[1]. For proof of concept, Cambridge Consultants designed a system to measure and monitor a participant’s stress levels during trials. Developed in consultation with clinical psychiatrists and neuroscientists, Verum harnesses the power of biometric data, primarily voice and electromyography (EMG), and machine learning to better understand outcomes and increase the likelihood of clinical success. This machine learning-driven system can provide deeper insight on participants during trials through real-time triggers and alerts, enabling clinicians, nurses and trial co-ordinators to mitigate the effect of stress on compliance, investigate stress as a confounding factor and inform better adaptive trial design through continuous data streams. With the average cost of a Phase 2 clinical trial ranging from $7 million to $19.6 million[2] and 80% of all clinical trials failing to reach completion[3] it’s clear that increased efficiency has the potential to deliver very significant savings.

Verum comprises sensors integrated into a wearable, a data collection app and a widget for healthcare dashboards that augments existing data with patient-specific predictions and alerts, for unprecedented clinical insight. Verum’s ability to provide rich, contextualized biometric information at both population and patient level has the potential to revolutionize precision medicine, post-market surveillance and drug development.

Verum works by enabling clinicians, nurses and trial co-ordinators to access biometric and behavioural data from continuously monitored patients, gaining valuable context around a specific condition. This is achieved by applying a machine learning algorithm to measure patient data, producing a single numerical estimator of a patient’s stress levels at any stage of the trial.

Commenting on Verum, Jaquie Finn, Head of Digital Health at Cambridge Consultants, said: “The rising cost of clinical trials, combined with the commercial risks of failure, mean it’s vital we’re able to harness the power of AI and continuous patient monitoring to mitigate the impact of stress on clinical trial outcomes. Verum informs better adaptive trial design through bigger, real-time contextualized data sets and will mark a step-change in the efficiency of clinical trials.”

Potential future applications of Verum include the diagnosis of neurological conditions, the post market surveillance of drugs, the development of closed loop therapeutics, rehabilitation and remote patient monitoring. Within the consumer space, Verum can enable consumer brands to gain measured, quantitative insights into the use of products during trials. This could accelerate the product development process and provide new insights to spark innovation.



Notes to editors

Cambridge Consultants (剑桥顾问公司)开发突破性产品,产生和授权知识产权,并为全球的客户提供商业资讯,解决与技术相关的关键问题。60多年来,公司一直致力于帮助客户转化商业机会,包括推出市场领先的产品,进入新市场,引入新技术扩大现有市场。公司拥有超过900名员工,包括工程师、科学家、数学家和设计师,遍布于英国剑桥、美国波士顿、东京和新加坡办事处,为医疗和生命科学、工业和能源、消费和零售以及通讯和基础设施等多个行业提供解决方案。欲了解更多信息,请访问:

Cambridge Consultants是 Capgemini Invent (凯捷集团的创新、咨询和转型品牌)的子公司。Capgemini Invent帮助管理者设想和构建他们组织的未来。公司在全球设有30多个办事处和25个创意工作室,是一支拥有7000多名员工的强大团队,将战略、技术、数据科学和创意设计与深厚的行业专业知识和洞察力相结合,开发新的数字解决方案和未来的商业模式。

凯捷集团是通过技术来为客户改造和管理业务的全球领导者,而Capgemini Invent是凯捷集团不可或缺的一部分。集团的宗旨是通过技术释放人类的潜能,实现包容性和可持续的未来。它是一个及负社会责任的多元化组织,在近50个国家拥有27万名团队成员。凭借其50年的悠久历史和深厚的行业专业知识,凯捷集团受到客户的信赖,在快速发展和充满创新的云、数据、人工智能、连接、软件、数字工程和平台技术的推动下,能够满足客户从战略、设计到运营的所有业务需求。集团2020年的全球营收为160亿欧元。

获得你想要的未来 |

Cambridge Consultants develops breakthrough products, creates and licenses intellectual property, and provides business consultancy in technology-critical issues for clients worldwide. For more than 50 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of more than 800 staff, including engineers, scientists, mathematicians and designers, in offices in Cambridge (UK), Boston (USA) and Singapore, Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, digital health, energy and wireless communications. For more information, visit:

Cambridge Consultants is part of Altran, a global leader in engineering and R&D services which offers its clients a new way to innovate. Altran works alongside its clients on every link in the value chain of their project, from conception to industrialisation. In 2015, the Altran group generated revenues of €1.945bn. With a headcount of more than 27,000 employees, Altran is present in more than 20 countries. For more information, visit:




Verum hero.jpg, 0.6MB
Verum infographic.jpg, 1.5MB
Verum laptop.jpg, 3.9MB
TimeOut Image Mobile Website.jpg, 3MB


WE Communications